Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Small cell lung cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,319 result(s) found for: Small cell lung cancer. Displaying page 66 of 66.
    «« First « Previous 58  59  60  61  62  63  64  65  66 
    EudraCT Number: 2015-002867-41 Sponsor Protocol Number: OPS-C-001/D-FR-01072-001 Start Date*: 2015-12-10
    Sponsor Name:Ipsen Pharma
    Full Title: An international multi-center, open-label study to evaluate safety, tolerability, biodistribution, dosimetry and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor positi...
    Medical condition: Neuroendocrine tumors (NETs)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (GB - no longer in EU/EEA) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001455-32 Sponsor Protocol Number: WIN001 Start Date*: 2017-12-15
    Sponsor Name:Worldwide Innovative Network Association
    Full Title: A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to mat...
    Medical condition: Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (EGFR mutation, ALK translocation, ROS1 mutation if available or MET exon 14 skipping ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000275-16 Sponsor Protocol Number: CT/12.02 Start Date*: 2012-07-24
    Sponsor Name:Hellenic Oncology Research Group (H.O.R.G.)
    Full Title: A pilot phase II trial of cabazitaxel in patients with metastatic NSCLC progressing after docetaxel-based treatment
    Medical condition: Patients with stage IIIB with pleural effusion or stage IV NSCLC with documented disease progression during or after completion of docetaxel-based treatment are eligible for the study.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002197-31 Sponsor Protocol Number: AFAMOSI Start Date*: 2020-05-12
    Sponsor Name:Universitätsmedizin Mainz, Interdisziplinäres Zentrum klinische Studien
    Full Title: AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compared to osimertinib in patients with EGFRmutated/T790M Mutat...
    Medical condition: EGFR mutated non-squamous NSCLC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038666 Respiratory and mediastinal neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006538-16 Sponsor Protocol Number: A6181114 Start Date*: 2007-03-30
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US
    Full Title: AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNI...
    Medical condition: Malignant Gastrointestinal Stromal Tumor (GIST), Metastatic Breast Cancer, Metastatic Renal Cell Cancer, Pancreatic Neuroendocrine Tumor, Hepatocellular Carcinoma, Prostate Cancer, Thyroid Cancer, ...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) DK (Prematurely Ended) GB (Completed) NL (Prematurely Ended) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000316-34 Sponsor Protocol Number: CCLR457X2101 Start Date*: 2015-03-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II multicenter, open-label study of CLR457 administered orally in adult patients with advanced solid malignancies
    Medical condition: Advanced solid malignancies
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005454-35 Sponsor Protocol Number: RG_15-235 Start Date*: 2016-09-23
    Sponsor Name:University of Birmingham
    Full Title: Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)
    Medical condition: Post-transplant lymphoproliferative disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051358 Post transplant lymphoproliferative disorder PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-001400-11 Sponsor Protocol Number: 20170543 Start Date*: 2019-11-14
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mu...
    Medical condition: KRAS p.G12C mutant advanced NSCLC, CRC, and other solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) ES (Temporarily Halted) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001923-11 Sponsor Protocol Number: 18-BI-1206-03 Start Date*: 2019-12-09
    Sponsor Name:BioInvent International AB
    Full Title: Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or Anti-PDL...
    Medical condition: Advanced solid tumors who have relapsed or are refractory to anti-PD1 or anti-PDL1 therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004325-23 Sponsor Protocol Number: TAK-981-1502 Start Date*: 2023-01-06
    Sponsor Name:Takeda Development Center Americas, Inc. (TDC Americas)
    Full Title: A Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors
    Medical condition: Advanced or Metastatic Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) HR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001329-29 Sponsor Protocol Number: TIG-006 Start Date*: 2021-07-15
    Sponsor Name:iTeos Belgium SA
    Full Title: A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors
    Medical condition: Advanced solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001326-15 Sponsor Protocol Number: RXDX-101-01 Start Date*: 2014-10-15
    Sponsor Name:Ignyta Inc.
    Full Title: A Phase 1/2a, Multicenter, Open-Label Study of Oral RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for TrkA, TrkB, TrkC, ROS1, or ALK Molecular Alter...
    Medical condition: Locally advanced or metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10065252 Solid tumor LLT
    17.0 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-003456-36 Sponsor Protocol Number: CL1-95012-001 Start Date*: 2021-08-09
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A first in human Phase 1/2 open-label, multicenter, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors
    Medical condition: Advanced and/or metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002719-23 Sponsor Protocol Number: BT8009-100 Start Date*: 2020-10-29
    Sponsor Name:BicycleTx Ltd.
    Full Title: BT8009-100: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies
    Medical condition: Nectin-4 Expressing Advanced Malignancies.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003658-13 Sponsor Protocol Number: EWING2008 Start Date*: 2009-03-19
    Sponsor Name:Universitaetsklinikum Muenster
    Full Title: EWING 2008
    Medical condition: Ewing sarcoma Malignant peripheral neuroectodermal tumour Askin tumour Atypical Ewing sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057846 Primitive neuroectodermal tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057656 Askin's tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015759 Extra-osseous Ewing's sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) BE (Completed) NL (Completed) SE (Completed) HU (Completed) FI (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004721-23 Sponsor Protocol Number: 20190135 Start Date*: 2022-01-28
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)
    Medical condition: Advanced Solid Tumors with KRAS p.G12C Mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) AT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-005189-75 Sponsor Protocol Number: BO39633 Start Date*: 2017-07-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY
    Medical condition: Cancer (Future parent protocols may include other cancer that are not included in this section)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046721 Urothelial carcinoma bladder stage III LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029514 Non-small cell lung cancer NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) BE (Completed) FR (Trial now transitioned) NL (Ongoing) SI (Completed) PT (Completed) DE (Completed) LV (Prematurely Ended) LT (Ongoing) SK (Prematurely Ended) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000340-26 Sponsor Protocol Number: CA027-002 Start Date*: 2018-10-31
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
    Medical condition: Advanced Cancers
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001093-11 Sponsor Protocol Number: A6181030 Start Date*: 2004-12-24
    Sponsor Name:Pfizer Global Research and Development
    Full Title: A Treatment Protocol for Patients Continuing from a Prior SU011248 Protocol
    Medical condition: This is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10062427 LLY
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) NL (Completed) SE (Completed) GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 58  59  60  61  62  63  64  65  66 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 13:07:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA